Novavax announced on June 14 that its COVID-19 vaccine proved effective in Phase III clinical trials. Its trial was also done on the variant of Coronavirus. The American biotechnology company said, “The vaccine is codenamed NVX-COV2373. Shown 90 percent effective in preventing COVID-19 and 100 percent effectiveness in preventing moderate to severe infections.”
The vaccine candidate developed with the Coalition for Epidemic Preparedness Innovation (CIPI) has shown 93 percent effectiveness against variants of concern and variants of interest.
It has also shown success among high-risk populations, including those over 65 years of age and those with comorbidities below the age of 65.
The dose for this two-shot vaccine needs to be kept between 2 and 8 °C. This will make it easier to story and move the vaccine. It is expected to play an important role in increasing the supply of vaccines, especially in developing countries.
However, the rollout of the vaccine is expected to take more time. The company said it plans to seek approval for the vaccine in the US, Europe and elsewhere by the end of September and will be able to make 100 million doses per month by then and 150 million doses per month by December.
The company is committed to supplying 110 million doses to the US next year and a total of 1.1 billion doses to developing countries.
In September 2020, Novavax announced that the Serum Institute of India (SII) would manufacture 1 billion doses of its vaccine in 2021. It has similar manufacturing partnerships in other countries including Japan.
Facebook us for social media updates (https://www.facebook.com/moneycontrolhindi/) and Twitter (https://twitter.com/MoneycontrolH) to follow.